Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study

European Journal of Preventive Cardiology

Volumn 14, Issue 5, 2007, Pages 638-645

  May, Margaret ^a   Lawlor, Debbie A ^a   Patel, Rita ^a   Rumley, Ann ^b   Lowe, Gordon ^b   Ebrahim, Shah ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

coronary heart disease; epidemiology; fibrin D dimer; thrombosis; tissue plasminogen activator; von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING HABIT; SOCIOECONOMICS; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY DISEASE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GREAT BRITAIN; HUMANS; MIDDLE AGED; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 35048878258     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3280e129d0     Document Type: Article

References (30)

1. Mannucci PM. von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359–1362.
2. Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: Poller L, Ludlam CA, editors. Recent advances in blood coagulation. Edinburgh: Churchill Livingstone; 1997: pp 69–96.
3. Lowe GDO, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667–672.
4. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci Mol Med 1995; 89: 205–214.
5. de Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504–507.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–126.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
8. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3: 1618–1627.
9. van der Bom JG, de Maat MP, Bots ML, Haverkate F, de Jong PT, Hofman A, et al. Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998; 18: 621–625.
10. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25: 1051–1056.
11. Lawlor DA, Davey Smith G, Rumley A, Lowe GD, Ebrahim S. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women's Heart and Health Study. Thromb Haemost 2005; 93: 955–963.
12. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366: 1954–1959.
13. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6–IV19.
14. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.
15. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25: 252–259.
16. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323–2327.
17. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003; 57: 134–140.
18. Lawlor DA, Davey Smith G, Ebrahim S. Life course influences on insulin resistance: findings from the British Women's Heart and Health Study. Diabetes Care 2003; 26: 97–103.
19. Lawlor DA, Ebrahim S, Davey Smith G. The association of socio-economic position across the life course and age at menopause: the British Women's Heart and Health Study. BJOG 2003; 110: 1078–1087.
20. Lowe GDO, Rumley A, Wannamethee G. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005; 3: 1076–1078.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
22. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681–694.
23. Royston P. Multiple imputation of missing values. Stata Journal 2004; 4: 227–241.
24. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987.
25. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, et al. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23: 1764–1770.
26. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799–1809.
27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304.
28. Levin RI. The puzzle of aspirin and sex. N Engl J Med 2005; 352: 1366–1368.
29. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295: 1420–1427.
30. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet 2006; 367: 651–658.